chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 62.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: None- vaccine given 6 days post expiry; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (None- vaccine given 6 days post expiry) in a 63-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 046C21A and 041L20A) for an unknown indication.     No Medical History information was reported.   On 13-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 12-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 12-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (None- vaccine given 6 days post expiry). On 12-Nov-2021, EXPIRED PRODUCT ADMINISTERED (None- vaccine given 6 days post expiry) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No Concomitant Medications details were provided. No Treatment Medications details were provided.   This case was linked to MOD-2021-395985 (Patient Link).
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: vaccine given 6 days post expiry; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (vaccine given 6 days post expiry) in a 62-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 046C21A and 041L20A) for COVID-19 vaccination.     No Medical History information was reported.   On 13-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 12-Nov-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced EXPIRED PRODUCT ADMINISTERED (vaccine given 6 days post expiry). On 12-Nov-2021, EXPIRED PRODUCT ADMINISTERED (vaccine given 6 days post expiry) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medications details were not reported by the reporter. Treatment details was not reported by the reporter.   This case was linked to MOD-2021-395985 (Patient Link).
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: vaccine given 6 days post expiry; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (vaccine given 6 days post expiry) in a 36-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 046C21A and 041L20A) for COVID-19 vaccination.     No Medical History information was reported.   On 15-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 12-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (vaccine given 6 days post expiry). On 12-Nov-2021, EXPIRED PRODUCT ADMINISTERED (vaccine given 6 days post expiry) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No Concomitant product use was reported. No treatment information was provided.   This case was linked to MOD-2021-395985 (Patient Link).
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: vaccine given 6 days post expiry; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (vaccine given 6 days post expiry) in a 56-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 046C21A and 011L20A) for COVID-19 vaccination.     No Medical History information was reported.   On 12-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 12-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (vaccine given 6 days post expiry). On 12-Nov-2021, EXPIRED PRODUCT ADMINISTERED (vaccine given 6 days post expiry) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported  No treatment medications were reported   This case was linked to MOD-2021-395985 (Patient Link).
Age: 53.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: None- vaccine given 17 days post expiry; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (None- vaccine given 17 days post expiry) in a 53-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 046C21A and 041L20A) for COVID-19 vaccination.     No Medical History information was reported.   On 14-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 23-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 23-Nov-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced EXPIRED PRODUCT ADMINISTERED (None- vaccine given 17 days post expiry). On 23-Nov-2021, EXPIRED PRODUCT ADMINISTERED (None- vaccine given 17 days post expiry) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No Concomitant medication were reported. No treatment medication were reported.   This case was linked to MOD-2021-395985 (Patient Link).
Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: vaccine given 6 days post expiry; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (vaccine given 6 days post expiry) in a 34-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 046C21A) for COVID-19 vaccination.     No Medical History information was reported.   On 02-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 12-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (vaccine given 6 days post expiry). On 12-Nov-2021, EXPIRED PRODUCT ADMINISTERED (vaccine given 6 days post expiry) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication was given.  No treatment medication was given.  No adverse event reported.   This case was linked to MOD-2021-395985 (Patient Link).
Age: 74.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: None- vaccine given 6 days post expiry; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (None- vaccine given 6 days post expiry) in a 74-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 046C21A and 011J20A) for COVID-19 vaccination.     No Medical History information was reported.   On 29-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 12-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 12-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (None- vaccine given 6 days post expiry). On 12-Nov-2021, EXPIRED PRODUCT ADMINISTERED (None- vaccine given 6 days post expiry) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No Concomitant Medications details were provided. No Treatment Medications details were provided.   This case was linked to MOD-2021-395985 (Patient Link).
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: vaccine given 6 days post expiry; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (vaccine given 6 days post expiry) in a 45-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 046C21A and 011L20A) for COVID-19 vaccination.     No Medical History information was reported.   On 12-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 12-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (vaccine given 6 days post expiry). On 12-Nov-2021, EXPIRED PRODUCT ADMINISTERED (vaccine given 6 days post expiry) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported.  Treatment information was not provided.   This case was linked to MOD-2021-395985 (Patient Link).
Age: 89.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: vaccine given 6 days post expiry; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (vaccine given 6 days post expiry) in an 89-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 046C21A and 041L20A) for COVID-19 vaccination.     No Medical History information was reported.   On 21-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 12-Nov-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced EXPIRED PRODUCT ADMINISTERED (vaccine given 6 days post expiry). On 12-Nov-2021, EXPIRED PRODUCT ADMINISTERED (vaccine given 6 days post expiry) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medications details were not reported by the reporter. Treatment details was not reported by the reporter.   This case was linked to MOD-2021-395985 (Patient Link).
Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Vaccine given 6 days post expiry; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Vaccine given 6 days post expiry) in a 56-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 046C21A and 011J20A) for COVID-19 vaccination.     No Medical History information was reported.   On 06-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 12-Nov-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced EXPIRED PRODUCT ADMINISTERED (Vaccine given 6 days post expiry). On 12-Nov-2021, EXPIRED PRODUCT ADMINISTERED (Vaccine given 6 days post expiry) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitants were provided. No treatment was provided.   This case was linked to MOD-2021-395985 (Patient Link).
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: None- vaccine given 6 days post expiry; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (None- vaccine given 6 days post expiry) in a 56-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 046C21A and 011L20A) for COVID-19 vaccination.     No Medical History information was reported.   On 12-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 12-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (None- vaccine given 6 days post expiry). On 12-Nov-2021, EXPIRED PRODUCT ADMINISTERED (None- vaccine given 6 days post expiry) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported.  No treatment medications were reported.   This case was linked to MOD-2021-395985 (Patient Link).
Age: 59.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: vaccine given 6 days post expiry; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (vaccine given 6 days post expiry) in a 59-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 046C21A and 011J20A) for COVID-19 vaccination.     No Medical History information was reported.   On 29-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 12-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (vaccine given 6 days post expiry). On 12-Nov-2021, EXPIRED PRODUCT ADMINISTERED (vaccine given 6 days post expiry) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No Concomitant medications were reported.  No Treatment information was reported.   This case was linked to MOD-2021-395985 (Patient Link).
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: None- vaccine given 12 days post expiry; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (None- vaccine given 12 days post expiry) in a 37-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 046C21A and 011J20A) for COVID-19 vaccination.     No Medical History information was reported.   On 30-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 18-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 18-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (None- vaccine given 12 days post expiry). On 18-Nov-2021, EXPIRED PRODUCT ADMINISTERED (None- vaccine given 12 days post expiry) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No treatment and concomitant medications were provided.   This case was linked to MOD-2021-395985 (Patient Link).
Age: 77.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Vaccine given 6 days post expiry; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Vaccine given 6 days post expiry) in a 78-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 046C21A and 011L20A) for COVID-19 vaccination.     No Medical History information was reported.   On 12-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 12-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Vaccine given 6 days post expiry). On 12-Nov-2021, EXPIRED PRODUCT ADMINISTERED (Vaccine given 6 days post expiry) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported. No treatment drug details were reported.   This case was linked to MOD-2021-395985 (Patient Link).
Age: 44.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: vaccine given 6 days post expiry; This spontaneous case was reported by a physician and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (vaccine given 6 days post expiry) in a 44-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 046C21A and 011L20A) for COVID-19 vaccination.     No Medical History information was reported.   On 12-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 12-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (vaccine given 6 days post expiry). On 12-Nov-2021, EXPIRED PRODUCT ADMINISTERED (vaccine given 6 days post expiry) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No relevant concomitant medications were provided. No treatment information was provided.   This case was linked to MOD-2021-395985 (Patient Link).
Age: 56.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: vaccine given 6 days post expiry; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (vaccine given 6 days post expiry) in a 56-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 046C21A and 011L20A) for COVID-19 vaccination.     No Medical History information was reported.   On 12-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 12-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Nov-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced EXPIRED PRODUCT ADMINISTERED (vaccine given 6 days post expiry). On 12-Nov-2021, EXPIRED PRODUCT ADMINISTERED (vaccine given 6 days post expiry) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medication information was not provided by the reporter.  Treatment information was not provided by the reporter.   This case was linked to MOD-2021-395985 (Patient Link).
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: vaccine given 6 days post expiry; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (vaccine given 6 days post expiry) in a 58-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 046C21A) for COVID-19 vaccination.     No Medical History information was reported.   On 02-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 12-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (vaccine given 6 days post expiry). On 12-Nov-2021, EXPIRED PRODUCT ADMINISTERED (vaccine given 6 days post expiry) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   no concomitant medication were reported no treatment medication were reported   This case was linked to MOD-2021-395985 (Patient Link).
Age: 54.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Axillary pain, Fatigue, Irritability, Rhinorrhoea
Clinical narrative: Severe armpit pain.  Knee pain.  Fatigue. Sole of feet very tender.  Irritability.  Runny nose.
Age: 54.0
Sex: F
Vaccine: COVID19
Symptoms: Tenderness
Clinical narrative: Severe armpit pain.  Knee pain.  Fatigue. Sole of feet very tender.  Irritability.  Runny nose.
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Adenovirus test, Arteriosclerosis coronary artery, Asthenia, Blood culture, Bordetella test negative
Clinical narrative: Patient discharged after (3) day inpatient admission.  The patient is a 51-year-old lady who presented to the hospital with chief complaint of worsening shortness of breath and cough.  The patient has the past medical history of type 2 diabetes mellitus, hypertension, psoriasis on methotrexate, GERD, hypothyroidism, chronic obstructive pulmonary disease, morbid is 3 common current tobacco abuse.  The patient stated she had developed the symptoms on Tuesday in the form of intermittent productive cough, progressive worsening shortness of breath, intermittent wheezing intermittent fevers and chills with nasal congestion, sore throat and decreased appetite, nausea, myalgia, generalized weakness and fatigue.  Denies any loss of taste or smell.  The patient also complained of some pleuritic chest pain.  Denies any recent medication changes patient is fully vaccinated and received a booster in August.  The patient does not use oxygen at home for her chronic obstructive pulmonary disease.  Denies any lightheadedness or dizziness or headache abdominal pain.  She did have some a minor bilateral pedal edema over the last few days.  Sh patient was found to be hypoxic with tachycardia and hypertension in the emergency department.  She was started on 3 L of nasal cannula to maintain her oxygen saturation.  She was found to have positive COVID PCR.  X-ray chest showed finding suggestive of pulmonary edema a bilateral mixed interstitial/airspace pneumonia.  She was started on IV Solu-Medrol and nebulizer treatments.  He was also started on Lasix.  The she underwent a CT angiogram of the thorax which did not reveal any pulmonary embolism.  However the multifocal tree-in-bud opacity, lung nodularity and interstitial thickening which is similar to the prior exams.  Concern for sarcoidosis was raised.  There was also evidence of right small pleural effusion and small pericardial effusion.  Patient also was found to have worsening mild mediastinal and hilar adenopathy is likely reactive.  She was started on a remdesivir as well for COVID.  Pulmonary service was consulted for concerns of lymphadenopathy, sarcoidosis expressed on the CT scan.Patient was seen by Pulmonary and they will follow her up as outpatient.Further workup once she recovers with repeat CT chest after 3 months.  Patient did well overall.  Her diabetes was managed.  She was subsequently discharged home
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Bronchial wall thickening, Bronchitis, COVID-19, Cardiac failure congestive, Cardiomegaly
Clinical narrative: Patient discharged after (3) day inpatient admission.  The patient is a 51-year-old lady who presented to the hospital with chief complaint of worsening shortness of breath and cough.  The patient has the past medical history of type 2 diabetes mellitus, hypertension, psoriasis on methotrexate, GERD, hypothyroidism, chronic obstructive pulmonary disease, morbid is 3 common current tobacco abuse.  The patient stated she had developed the symptoms on Tuesday in the form of intermittent productive cough, progressive worsening shortness of breath, intermittent wheezing intermittent fevers and chills with nasal congestion, sore throat and decreased appetite, nausea, myalgia, generalized weakness and fatigue.  Denies any loss of taste or smell.  The patient also complained of some pleuritic chest pain.  Denies any recent medication changes patient is fully vaccinated and received a booster in August.  The patient does not use oxygen at home for her chronic obstructive pulmonary disease.  Denies any lightheadedness or dizziness or headache abdominal pain.  She did have some a minor bilateral pedal edema over the last few days.  Sh patient was found to be hypoxic with tachycardia and hypertension in the emergency department.  She was started on 3 L of nasal cannula to maintain her oxygen saturation.  She was found to have positive COVID PCR.  X-ray chest showed finding suggestive of pulmonary edema a bilateral mixed interstitial/airspace pneumonia.  She was started on IV Solu-Medrol and nebulizer treatments.  He was also started on Lasix.  The she underwent a CT angiogram of the thorax which did not reveal any pulmonary embolism.  However the multifocal tree-in-bud opacity, lung nodularity and interstitial thickening which is similar to the prior exams.  Concern for sarcoidosis was raised.  There was also evidence of right small pleural effusion and small pericardial effusion.  Patient also was found to have worsening mild mediastinal and hilar adenopathy is likely reactive.  She was started on a remdesivir as well for COVID.  Pulmonary service was consulted for concerns of lymphadenopathy, sarcoidosis expressed on the CT scan.Patient was seen by Pulmonary and they will follow her up as outpatient.Further workup once she recovers with repeat CT chest after 3 months.  Patient did well overall.  Her diabetes was managed.  She was subsequently discharged home
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Chest X-ray abnormal, Chills, Chlamydia test negative, Computerised tomogram thorax, Computerised tomogram thorax abnormal
Clinical narrative: Patient discharged after (3) day inpatient admission.  The patient is a 51-year-old lady who presented to the hospital with chief complaint of worsening shortness of breath and cough.  The patient has the past medical history of type 2 diabetes mellitus, hypertension, psoriasis on methotrexate, GERD, hypothyroidism, chronic obstructive pulmonary disease, morbid is 3 common current tobacco abuse.  The patient stated she had developed the symptoms on Tuesday in the form of intermittent productive cough, progressive worsening shortness of breath, intermittent wheezing intermittent fevers and chills with nasal congestion, sore throat and decreased appetite, nausea, myalgia, generalized weakness and fatigue.  Denies any loss of taste or smell.  The patient also complained of some pleuritic chest pain.  Denies any recent medication changes patient is fully vaccinated and received a booster in August.  The patient does not use oxygen at home for her chronic obstructive pulmonary disease.  Denies any lightheadedness or dizziness or headache abdominal pain.  She did have some a minor bilateral pedal edema over the last few days.  Sh patient was found to be hypoxic with tachycardia and hypertension in the emergency department.  She was started on 3 L of nasal cannula to maintain her oxygen saturation.  She was found to have positive COVID PCR.  X-ray chest showed finding suggestive of pulmonary edema a bilateral mixed interstitial/airspace pneumonia.  She was started on IV Solu-Medrol and nebulizer treatments.  He was also started on Lasix.  The she underwent a CT angiogram of the thorax which did not reveal any pulmonary embolism.  However the multifocal tree-in-bud opacity, lung nodularity and interstitial thickening which is similar to the prior exams.  Concern for sarcoidosis was raised.  There was also evidence of right small pleural effusion and small pericardial effusion.  Patient also was found to have worsening mild mediastinal and hilar adenopathy is likely reactive.  She was started on a remdesivir as well for COVID.  Pulmonary service was consulted for concerns of lymphadenopathy, sarcoidosis expressed on the CT scan.Patient was seen by Pulmonary and they will follow her up as outpatient.Further workup once she recovers with repeat CT chest after 3 months.  Patient did well overall.  Her diabetes was managed.  She was subsequently discharged home
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Condition aggravated, Coronavirus test negative, Decreased appetite, Dyspnoea, Echocardiogram
Clinical narrative: Patient discharged after (3) day inpatient admission.  The patient is a 51-year-old lady who presented to the hospital with chief complaint of worsening shortness of breath and cough.  The patient has the past medical history of type 2 diabetes mellitus, hypertension, psoriasis on methotrexate, GERD, hypothyroidism, chronic obstructive pulmonary disease, morbid is 3 common current tobacco abuse.  The patient stated she had developed the symptoms on Tuesday in the form of intermittent productive cough, progressive worsening shortness of breath, intermittent wheezing intermittent fevers and chills with nasal congestion, sore throat and decreased appetite, nausea, myalgia, generalized weakness and fatigue.  Denies any loss of taste or smell.  The patient also complained of some pleuritic chest pain.  Denies any recent medication changes patient is fully vaccinated and received a booster in August.  The patient does not use oxygen at home for her chronic obstructive pulmonary disease.  Denies any lightheadedness or dizziness or headache abdominal pain.  She did have some a minor bilateral pedal edema over the last few days.  Sh patient was found to be hypoxic with tachycardia and hypertension in the emergency department.  She was started on 3 L of nasal cannula to maintain her oxygen saturation.  She was found to have positive COVID PCR.  X-ray chest showed finding suggestive of pulmonary edema a bilateral mixed interstitial/airspace pneumonia.  She was started on IV Solu-Medrol and nebulizer treatments.  He was also started on Lasix.  The she underwent a CT angiogram of the thorax which did not reveal any pulmonary embolism.  However the multifocal tree-in-bud opacity, lung nodularity and interstitial thickening which is similar to the prior exams.  Concern for sarcoidosis was raised.  There was also evidence of right small pleural effusion and small pericardial effusion.  Patient also was found to have worsening mild mediastinal and hilar adenopathy is likely reactive.  She was started on a remdesivir as well for COVID.  Pulmonary service was consulted for concerns of lymphadenopathy, sarcoidosis expressed on the CT scan.Patient was seen by Pulmonary and they will follow her up as outpatient.Further workup once she recovers with repeat CT chest after 3 months.  Patient did well overall.  Her diabetes was managed.  She was subsequently discharged home
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Echocardiogram abnormal, Ejection fraction, Enterovirus test negative, Fatigue, Fibrin D dimer increased
Clinical narrative: Patient discharged after (3) day inpatient admission.  The patient is a 51-year-old lady who presented to the hospital with chief complaint of worsening shortness of breath and cough.  The patient has the past medical history of type 2 diabetes mellitus, hypertension, psoriasis on methotrexate, GERD, hypothyroidism, chronic obstructive pulmonary disease, morbid is 3 common current tobacco abuse.  The patient stated she had developed the symptoms on Tuesday in the form of intermittent productive cough, progressive worsening shortness of breath, intermittent wheezing intermittent fevers and chills with nasal congestion, sore throat and decreased appetite, nausea, myalgia, generalized weakness and fatigue.  Denies any loss of taste or smell.  The patient also complained of some pleuritic chest pain.  Denies any recent medication changes patient is fully vaccinated and received a booster in August.  The patient does not use oxygen at home for her chronic obstructive pulmonary disease.  Denies any lightheadedness or dizziness or headache abdominal pain.  She did have some a minor bilateral pedal edema over the last few days.  Sh patient was found to be hypoxic with tachycardia and hypertension in the emergency department.  She was started on 3 L of nasal cannula to maintain her oxygen saturation.  She was found to have positive COVID PCR.  X-ray chest showed finding suggestive of pulmonary edema a bilateral mixed interstitial/airspace pneumonia.  She was started on IV Solu-Medrol and nebulizer treatments.  He was also started on Lasix.  The she underwent a CT angiogram of the thorax which did not reveal any pulmonary embolism.  However the multifocal tree-in-bud opacity, lung nodularity and interstitial thickening which is similar to the prior exams.  Concern for sarcoidosis was raised.  There was also evidence of right small pleural effusion and small pericardial effusion.  Patient also was found to have worsening mild mediastinal and hilar adenopathy is likely reactive.  She was started on a remdesivir as well for COVID.  Pulmonary service was consulted for concerns of lymphadenopathy, sarcoidosis expressed on the CT scan.Patient was seen by Pulmonary and they will follow her up as outpatient.Further workup once she recovers with repeat CT chest after 3 months.  Patient did well overall.  Her diabetes was managed.  She was subsequently discharged home
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Hilar lymphadenopathy, Human metapneumovirus test, Human rhinovirus test, Hypertension, Hypoxia
Clinical narrative: Patient discharged after (3) day inpatient admission.  The patient is a 51-year-old lady who presented to the hospital with chief complaint of worsening shortness of breath and cough.  The patient has the past medical history of type 2 diabetes mellitus, hypertension, psoriasis on methotrexate, GERD, hypothyroidism, chronic obstructive pulmonary disease, morbid is 3 common current tobacco abuse.  The patient stated she had developed the symptoms on Tuesday in the form of intermittent productive cough, progressive worsening shortness of breath, intermittent wheezing intermittent fevers and chills with nasal congestion, sore throat and decreased appetite, nausea, myalgia, generalized weakness and fatigue.  Denies any loss of taste or smell.  The patient also complained of some pleuritic chest pain.  Denies any recent medication changes patient is fully vaccinated and received a booster in August.  The patient does not use oxygen at home for her chronic obstructive pulmonary disease.  Denies any lightheadedness or dizziness or headache abdominal pain.  She did have some a minor bilateral pedal edema over the last few days.  Sh patient was found to be hypoxic with tachycardia and hypertension in the emergency department.  She was started on 3 L of nasal cannula to maintain her oxygen saturation.  She was found to have positive COVID PCR.  X-ray chest showed finding suggestive of pulmonary edema a bilateral mixed interstitial/airspace pneumonia.  She was started on IV Solu-Medrol and nebulizer treatments.  He was also started on Lasix.  The she underwent a CT angiogram of the thorax which did not reveal any pulmonary embolism.  However the multifocal tree-in-bud opacity, lung nodularity and interstitial thickening which is similar to the prior exams.  Concern for sarcoidosis was raised.  There was also evidence of right small pleural effusion and small pericardial effusion.  Patient also was found to have worsening mild mediastinal and hilar adenopathy is likely reactive.  She was started on a remdesivir as well for COVID.  Pulmonary service was consulted for concerns of lymphadenopathy, sarcoidosis expressed on the CT scan.Patient was seen by Pulmonary and they will follow her up as outpatient.Further workup once she recovers with repeat CT chest after 3 months.  Patient did well overall.  Her diabetes was managed.  She was subsequently discharged home
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Inferior vena cava dilatation, Influenza A virus test negative, Influenza B virus test, Influenza virus test negative, Interstitial lung disease
Clinical narrative: Patient discharged after (3) day inpatient admission.  The patient is a 51-year-old lady who presented to the hospital with chief complaint of worsening shortness of breath and cough.  The patient has the past medical history of type 2 diabetes mellitus, hypertension, psoriasis on methotrexate, GERD, hypothyroidism, chronic obstructive pulmonary disease, morbid is 3 common current tobacco abuse.  The patient stated she had developed the symptoms on Tuesday in the form of intermittent productive cough, progressive worsening shortness of breath, intermittent wheezing intermittent fevers and chills with nasal congestion, sore throat and decreased appetite, nausea, myalgia, generalized weakness and fatigue.  Denies any loss of taste or smell.  The patient also complained of some pleuritic chest pain.  Denies any recent medication changes patient is fully vaccinated and received a booster in August.  The patient does not use oxygen at home for her chronic obstructive pulmonary disease.  Denies any lightheadedness or dizziness or headache abdominal pain.  She did have some a minor bilateral pedal edema over the last few days.  Sh patient was found to be hypoxic with tachycardia and hypertension in the emergency department.  She was started on 3 L of nasal cannula to maintain her oxygen saturation.  She was found to have positive COVID PCR.  X-ray chest showed finding suggestive of pulmonary edema a bilateral mixed interstitial/airspace pneumonia.  She was started on IV Solu-Medrol and nebulizer treatments.  He was also started on Lasix.  The she underwent a CT angiogram of the thorax which did not reveal any pulmonary embolism.  However the multifocal tree-in-bud opacity, lung nodularity and interstitial thickening which is similar to the prior exams.  Concern for sarcoidosis was raised.  There was also evidence of right small pleural effusion and small pericardial effusion.  Patient also was found to have worsening mild mediastinal and hilar adenopathy is likely reactive.  She was started on a remdesivir as well for COVID.  Pulmonary service was consulted for concerns of lymphadenopathy, sarcoidosis expressed on the CT scan.Patient was seen by Pulmonary and they will follow her up as outpatient.Further workup once she recovers with repeat CT chest after 3 months.  Patient did well overall.  Her diabetes was managed.  She was subsequently discharged home
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Left ventricular hypertrophy, Lung opacity, Lymphadenopathy mediastinal, Mitral valve incompetence, Myalgia
Clinical narrative: Patient discharged after (3) day inpatient admission.  The patient is a 51-year-old lady who presented to the hospital with chief complaint of worsening shortness of breath and cough.  The patient has the past medical history of type 2 diabetes mellitus, hypertension, psoriasis on methotrexate, GERD, hypothyroidism, chronic obstructive pulmonary disease, morbid is 3 common current tobacco abuse.  The patient stated she had developed the symptoms on Tuesday in the form of intermittent productive cough, progressive worsening shortness of breath, intermittent wheezing intermittent fevers and chills with nasal congestion, sore throat and decreased appetite, nausea, myalgia, generalized weakness and fatigue.  Denies any loss of taste or smell.  The patient also complained of some pleuritic chest pain.  Denies any recent medication changes patient is fully vaccinated and received a booster in August.  The patient does not use oxygen at home for her chronic obstructive pulmonary disease.  Denies any lightheadedness or dizziness or headache abdominal pain.  She did have some a minor bilateral pedal edema over the last few days.  Sh patient was found to be hypoxic with tachycardia and hypertension in the emergency department.  She was started on 3 L of nasal cannula to maintain her oxygen saturation.  She was found to have positive COVID PCR.  X-ray chest showed finding suggestive of pulmonary edema a bilateral mixed interstitial/airspace pneumonia.  She was started on IV Solu-Medrol and nebulizer treatments.  He was also started on Lasix.  The she underwent a CT angiogram of the thorax which did not reveal any pulmonary embolism.  However the multifocal tree-in-bud opacity, lung nodularity and interstitial thickening which is similar to the prior exams.  Concern for sarcoidosis was raised.  There was also evidence of right small pleural effusion and small pericardial effusion.  Patient also was found to have worsening mild mediastinal and hilar adenopathy is likely reactive.  She was started on a remdesivir as well for COVID.  Pulmonary service was consulted for concerns of lymphadenopathy, sarcoidosis expressed on the CT scan.Patient was seen by Pulmonary and they will follow her up as outpatient.Further workup once she recovers with repeat CT chest after 3 months.  Patient did well overall.  Her diabetes was managed.  She was subsequently discharged home
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Mycoplasma test negative, Nasal congestion, Nausea, Oedema peripheral, Oropharyngeal pain
Clinical narrative: Patient discharged after (3) day inpatient admission.  The patient is a 51-year-old lady who presented to the hospital with chief complaint of worsening shortness of breath and cough.  The patient has the past medical history of type 2 diabetes mellitus, hypertension, psoriasis on methotrexate, GERD, hypothyroidism, chronic obstructive pulmonary disease, morbid is 3 common current tobacco abuse.  The patient stated she had developed the symptoms on Tuesday in the form of intermittent productive cough, progressive worsening shortness of breath, intermittent wheezing intermittent fevers and chills with nasal congestion, sore throat and decreased appetite, nausea, myalgia, generalized weakness and fatigue.  Denies any loss of taste or smell.  The patient also complained of some pleuritic chest pain.  Denies any recent medication changes patient is fully vaccinated and received a booster in August.  The patient does not use oxygen at home for her chronic obstructive pulmonary disease.  Denies any lightheadedness or dizziness or headache abdominal pain.  She did have some a minor bilateral pedal edema over the last few days.  Sh patient was found to be hypoxic with tachycardia and hypertension in the emergency department.  She was started on 3 L of nasal cannula to maintain her oxygen saturation.  She was found to have positive COVID PCR.  X-ray chest showed finding suggestive of pulmonary edema a bilateral mixed interstitial/airspace pneumonia.  She was started on IV Solu-Medrol and nebulizer treatments.  He was also started on Lasix.  The she underwent a CT angiogram of the thorax which did not reveal any pulmonary embolism.  However the multifocal tree-in-bud opacity, lung nodularity and interstitial thickening which is similar to the prior exams.  Concern for sarcoidosis was raised.  There was also evidence of right small pleural effusion and small pericardial effusion.  Patient also was found to have worsening mild mediastinal and hilar adenopathy is likely reactive.  She was started on a remdesivir as well for COVID.  Pulmonary service was consulted for concerns of lymphadenopathy, sarcoidosis expressed on the CT scan.Patient was seen by Pulmonary and they will follow her up as outpatient.Further workup once she recovers with repeat CT chest after 3 months.  Patient did well overall.  Her diabetes was managed.  She was subsequently discharged home
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Pericardial effusion, Pleural effusion, Pleuritic pain, Productive cough, Pulmonary mass
Clinical narrative: Patient discharged after (3) day inpatient admission.  The patient is a 51-year-old lady who presented to the hospital with chief complaint of worsening shortness of breath and cough.  The patient has the past medical history of type 2 diabetes mellitus, hypertension, psoriasis on methotrexate, GERD, hypothyroidism, chronic obstructive pulmonary disease, morbid is 3 common current tobacco abuse.  The patient stated she had developed the symptoms on Tuesday in the form of intermittent productive cough, progressive worsening shortness of breath, intermittent wheezing intermittent fevers and chills with nasal congestion, sore throat and decreased appetite, nausea, myalgia, generalized weakness and fatigue.  Denies any loss of taste or smell.  The patient also complained of some pleuritic chest pain.  Denies any recent medication changes patient is fully vaccinated and received a booster in August.  The patient does not use oxygen at home for her chronic obstructive pulmonary disease.  Denies any lightheadedness or dizziness or headache abdominal pain.  She did have some a minor bilateral pedal edema over the last few days.  Sh patient was found to be hypoxic with tachycardia and hypertension in the emergency department.  She was started on 3 L of nasal cannula to maintain her oxygen saturation.  She was found to have positive COVID PCR.  X-ray chest showed finding suggestive of pulmonary edema a bilateral mixed interstitial/airspace pneumonia.  She was started on IV Solu-Medrol and nebulizer treatments.  He was also started on Lasix.  The she underwent a CT angiogram of the thorax which did not reveal any pulmonary embolism.  However the multifocal tree-in-bud opacity, lung nodularity and interstitial thickening which is similar to the prior exams.  Concern for sarcoidosis was raised.  There was also evidence of right small pleural effusion and small pericardial effusion.  Patient also was found to have worsening mild mediastinal and hilar adenopathy is likely reactive.  She was started on a remdesivir as well for COVID.  Pulmonary service was consulted for concerns of lymphadenopathy, sarcoidosis expressed on the CT scan.Patient was seen by Pulmonary and they will follow her up as outpatient.Further workup once she recovers with repeat CT chest after 3 months.  Patient did well overall.  Her diabetes was managed.  She was subsequently discharged home